WO2009120619A3 - Nuclease compositions, methods of making and using such compositions, and systems for pulmonary delivery of such compositions - Google Patents

Nuclease compositions, methods of making and using such compositions, and systems for pulmonary delivery of such compositions Download PDF

Info

Publication number
WO2009120619A3
WO2009120619A3 PCT/US2009/037930 US2009037930W WO2009120619A3 WO 2009120619 A3 WO2009120619 A3 WO 2009120619A3 US 2009037930 W US2009037930 W US 2009037930W WO 2009120619 A3 WO2009120619 A3 WO 2009120619A3
Authority
WO
WIPO (PCT)
Prior art keywords
compositions
nuclease
methods
systems
making
Prior art date
Application number
PCT/US2009/037930
Other languages
French (fr)
Other versions
WO2009120619A2 (en
Inventor
Jeffry G. Weers
Mei-Chang Kuo
Thomas Tarara
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of WO2009120619A2 publication Critical patent/WO2009120619A2/en
Publication of WO2009120619A3 publication Critical patent/WO2009120619A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules

Abstract

A powder composition comprises particles including a nuclease, wherein the particles have a mass median aerodynamic diameter ranging from about 1 µm to about 5 µm. A pharmaceutical composition comprises a powder including an effective amount of nuclease and pharmaceutically acceptable excipient, wherein the powder comprises particles comprising less than 40 wt% of nuclease and having a mass median aerodynamic diameter ranging from about 1 µm to about 5 µm. Unit dosage forms, spray drying methods, and methods of treatment are also included.
PCT/US2009/037930 2008-03-24 2009-03-23 Nuclease compositions, methods of making and using such compositions, and systems for pulmonary delivery of such compositions WO2009120619A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US7069308P 2008-03-24 2008-03-24
US61/070,693 2008-03-24

Publications (2)

Publication Number Publication Date
WO2009120619A2 WO2009120619A2 (en) 2009-10-01
WO2009120619A3 true WO2009120619A3 (en) 2010-07-01

Family

ID=40635460

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2009/037930 WO2009120619A2 (en) 2008-03-24 2009-03-23 Nuclease compositions, methods of making and using such compositions, and systems for pulmonary delivery of such compositions

Country Status (1)

Country Link
WO (1) WO2009120619A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW465235B (en) 1998-09-17 2001-11-21 United Video Properties Inc Electronic program guide with digital storage
KR101424518B1 (en) 2005-09-29 2014-08-06 노바르티스 아게 Antibiotic formulations, unit doses, kits, and methods

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995023613A1 (en) * 1994-03-04 1995-09-08 Genentech, Inc. PHARMACEUTICALLY ACCEPTABLE DNase FORMULATION
WO1999016419A1 (en) * 1997-09-29 1999-04-08 Inhale Therapeutic Systems, Inc. Perforated microparticles and methods of use
WO2001032144A1 (en) * 1999-10-29 2001-05-10 Inhale Therapeutic Systems, Inc. Dry powder compositions having improved dispersivity
US6309623B1 (en) * 1997-09-29 2001-10-30 Inhale Therapeutic Systems, Inc. Stabilized preparations for use in metered dose inhalers
WO2001085137A2 (en) * 2000-05-10 2001-11-15 Inhale Therapeutic Systems, Inc. Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery and methods of use
WO2008039989A2 (en) * 2006-09-28 2008-04-03 Transave, Inc. Formulations of dnase and methods of use thereof

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995023613A1 (en) * 1994-03-04 1995-09-08 Genentech, Inc. PHARMACEUTICALLY ACCEPTABLE DNase FORMULATION
WO1999016419A1 (en) * 1997-09-29 1999-04-08 Inhale Therapeutic Systems, Inc. Perforated microparticles and methods of use
US6309623B1 (en) * 1997-09-29 2001-10-30 Inhale Therapeutic Systems, Inc. Stabilized preparations for use in metered dose inhalers
WO2001032144A1 (en) * 1999-10-29 2001-05-10 Inhale Therapeutic Systems, Inc. Dry powder compositions having improved dispersivity
WO2001085137A2 (en) * 2000-05-10 2001-11-15 Inhale Therapeutic Systems, Inc. Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery and methods of use
WO2008039989A2 (en) * 2006-09-28 2008-04-03 Transave, Inc. Formulations of dnase and methods of use thereof

Also Published As

Publication number Publication date
WO2009120619A2 (en) 2009-10-01

Similar Documents

Publication Publication Date Title
WO2008053253A3 (en) Inhaler devices and bespoke pharmaceutical compositions
WO2006002140A3 (en) Compositions comprising amphotericin b
WO2012016889A3 (en) Dry powder formulation comprising a phosphodiesterase inhibitor
WO2007123955A3 (en) Stable hydroalcoholic oral spray formulations and methods
WO2005025535A3 (en) Methods for preparing pharmaceutical compositions
MX2017016274A (en) Orodispersible dosage unit containing an estetrol component.
NZ707551A (en) Prostacyclin compositions and methods for using the same
NZ603042A (en) Pharmaceutical compositions comprising cftr modulators and administrations thereof
WO2008063910A3 (en) Method of preparing solid dosage forms of multi-phasic pharmaceutical compositions
WO2007086914A3 (en) Nanoparticulate clopidogrel formulations
SG150075A1 (en) Particles for delivery of active ingredients, process of making and compositions thereof
WO2013090278A3 (en) Intranasal dexmedetomidine compositions and methods of use thereof
EP3626253A3 (en) Stable formulations of linaclotide
HRP20220929T3 (en) Inhalation composition containing aclidinium for treatment of asthma
WO2010010257A3 (en) Appetising medicaments for oral administration in solid form for prevention and/or treatment of cardiac insufficiency in animals
WO2010097243A3 (en) Process for forming solid oral dosage forms of solifenacin and its pharmaceutically acceptable salts
WO2008023016A3 (en) Galenic formulations of aliskiren
WO2013183062A3 (en) Palatable formulations of ibuprofen
WO2009074286A3 (en) Pharmaceutical formulation comprising ezetimibe
MY175781A (en) Composition comprising at least two dry powders obtained by spray drying to increase the stability of the formulation
WO2011051968A3 (en) Pharmaceutical compositions of lanthanum carbonate and process for the preparation thereof
WO2011056785A3 (en) Microcrystalline cellulose and calcium phosphate compositions useful as pharmaceutical excipients
WO2009084041A3 (en) Pharmaceutical compositions of dexibuprofen
MX2017004476A (en) Composition comprising at least one dry powder obtained by spray drying to increase the stability of the formulation.
WO2009120619A3 (en) Nuclease compositions, methods of making and using such compositions, and systems for pulmonary delivery of such compositions

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09725579

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 09725579

Country of ref document: EP

Kind code of ref document: A2